Human immunodeficiency virus type 1 infects human helper T lymphocytes by an interaction between gpl20, the viral coat protein, and the T-cell receptor CD4. Two microtiter-based immunoassays, an enzyme-linked immunosorbent assay (ELISA) and a particle concentration fluorescence assay, were developed to measure gpl20-CD4 binding and were then used to screen a variety of compounds for the inhibition of this interaction. Additional protocols, called "consumption assays," were defined to distinguish inhibitors which functioned by sequestering either gpl20 or CD4 to prevent the final effective bimolecular interaction. Monoclonal antibodies of defined specificity and compounds known from other published studies to inhibit gp120-CD4 binding were tested in an attempt to validate the assays used in the study. Once the capacity of these assays to detect known gpl20-CD4 inhibitors was confirmed, they were used to screen synthetic agents and fermentation broths for novel compounds that might be used as human immunodeficiency virus receptor antagonists. A 2,4-diaminoquinazoline, CP-101,816-1, was found to inhibit this interaction (50%Yo inhibitory concentration in ELISA, 32.5 ,ug/ml) and to interact more strongly with CD4 than with gpl20 in the consumption assays. The identification of a novel inhibitor, a 2,4-diaminoquinazoline, confirmed that such assays are useful for the detection of human immunodeficiency virus type 1 receptor antagonists.
A major target of human immunodeficiency virus type 1 (HIV-1) is the helper T lymphocyte, with HIV-1 entering the cell via the CD4 receptor that normally recognizes major histocompatibility complex class II antigens on antigen-presenting cells (7, 8) . The viral surface glycoprotein gpl20 interacts with this receptor, leading to virus-cell fusion and infection (9) . In addition, infected cells express gpl20 on their surfaces. These cells can fuse in turn with uninfected CD4-expressing T lymphocytes to form giant cells or syncytia. This is believed to contribute to the cytopathogenicity of HIV-1 in vitro and perhaps in vivo (2, 16) . Thus, a potential target for the chemotherapy of HIV-1 infection is the gpl20-CD4 interaction.
The availability of recombinant, soluble versions of gpl20 and CD4 made possible the development of several acellular assays to model the gpl20-CD4 interaction and of variations of these assays which predict the mechanism of action of lowmolecular-weight inhibitors. By using such assays, a synthetic agent, a 2,4-diaminoquinazoline, was identified as a novel inhibitor of gpl20-CD4 binding, and its mechanism of action was elucidated.
MATERIALS AND METHODS
Antiviral compounds and natural products. The L,L and D,D stereoisomers of N-carbomethoxycarbonyl-prolyl-phenylalanyl benzyl ester [CPF(LL) and CPF(DD), respectively], CP-101,816-1, and UK-22,233 were synthesized by conventional methods. Poly(sodium 4-styrenesulfonate) was purchased from Aldrich.
Bovine serum albumin (BSA; fraction V, fatty acid ultra free) was from Boehringer Mannheim. Pradimicin A was fermented and purified by the methods of Oki et al. (12) , with some modifications. The sample used in the assays was >90% pure. Other compounds were from Sigma.
PCFIA to detect inhibitors of gp120-CD4 binding. A rapid and simple particle concentration fluorescence immunoassay (PCFIA) similar to that of McQuade et al. (10) was developed in which anti-gp120 monoclonal antibody (MAb) was bound to submicron-size polystyrene particles. This served as a solid phase to capture the gpl20-CD4 receptor complex in the presence and absence of possible inhibitors. The complex was quantitated with fluorescein isothiocyanate (FITC)-labeled OkT4 (anti-CD4 MAb) in a fluorescence concentration analyzer.
Capture particles were prepared by binding an anti-gp120 mouse MAb (NEA-9284; NEN-DuPont) to polystyrene particles. NEA-9284 (NEN-DuPont) was dissolved in 0.1 M sodium phosphate buffer (pH 5.0) at 100 ,ug/ml. To 1.0 ml of antibody, 100 ,ul of 5.0% (wt/vol) polystyrene particle suspension (0.85-,um polystyrene particles; IDEXX) was added. The mixture was vortexed and incubated for 1 h at room temperature. The suspension was spun for 15 min at maximum speed in a microcentrifuge. The supernatant solution was removed, and the antibody-coated particles were washed with 2.0 ml of 0.1 M phosphate buffer. The particles were resuspended in 2.0 ml of phosphate-buffered saline (PBS) plus 1.0% BSA.
Twenty microliters of test compound in PBS plus initial solvents was pipetted into a filter-bottomed microtiter plate (Pandex). Twenty microliters of PBS plus 1.0% BSA containing 0.05 pmol of recombinant gp120 (Celltech) was added. A total of 0. antagonists that bind gpl20 from those that bind CD4. The immunoassays shown schematically in Fig. 1 were developed to distinguish HIV-1 receptor antagonists that bind gpl20 from those that bind CD4. To test gpl20 consumption, gpl20 was preincubated with inhibitor, unbound inhibitor was washed away, and the capacity of the putative inhibitor-gpl2O complex to bind CD4 was quantitated. CD4 consumption was determined simultaneously as the capacity of this inhibitor to combine with CD4 and thereby block the CD4-gpl2O interaction. Anti-CD4 or anti-gpl20 MAbs were used to "capture" putative inhibitor-CD4 and inhibitor-gpl2O complexes, respectively. The wells were washed to remove unbound inhibitor, and the complementary ligand (gpl20 to captured CD4 and CD4 to captured gpl20) was added. The bound complexes were visualized by standard methods. The inhibitors that interacted with gpl20 or CD4 in these assays so that they could not interact with their complementary ligand caused a doserelated decrease in the signal. CD4 consumption assay. The mouse anti-CD4 MAb OkT4 was diluted to 3.0,g/ml in 0.05 M Tris coating buffer (pH 7.4), and 100,lI of this was added to each well of a microtiter plate.
After overnight incubation at 4°C, each well was washed four times with 300 RI of TBS and was blocked with 300 RI of 3%
BSA at 37°C for 1 h. Each well was again washed four times with TBS containing 0.05% Tween 20.
To each well, 0.6 pmol of sCD4 in 50 ,ul ofTTB mixed with either 50 RI of test compound or buffer was added. The plate was incubated at 37°C for 1 h. The plate was washed four times with TBS-Tween, and 0.3 pmol of gpl20 was added to each well along with 100 RI of TTLB. The plate was incubated for another hour at 37°C and was again washed four times.
Human anti-HIV-1 IgG (Epitope) was diluted 1:100 with 1TB; 100 RI was added to each well, and the plate was incubated for 1 h at 37°C. The plate was washed as described above. Goat anti-human IgG conjugated to AP was diluted 1:2,000 with TlB, and 100 RI was added to each well. The plate was incubated for 1 h at room temperature and was then washed as described above. AP activity was detected and measured as described above. Percent inhibition was calculated as described above. Compounds that bound to and sequestered sCD4 caused inhibition of the signal when they were preincubated with CD4 but not with gpl20 or either capture antibody. rabbit IgG conjugated to AP was diluted 1:16,000 with TUB, and 100 RI was added to each well. The plate was incubated for 1 h at room temperature and the optical density of each well was measured as described above. Percent inhibition was calculated as described above. The compounds that sequestered gpl20 caused inhibition of the signal when they were preincubated with gp120, but not sCD4 or either capture antibody.
CCSAs. Cocultivation syncytium assays (CCSAs) were performed by using the CHO (pIII env3) cell line expressing gpl20 and the human CD4-expressing lymphocytic cell line Sup Ti and by the procedures of Walker et al. (21) .
RESULTS
Effect of blocking and non-specific MAbs in gp120-CD4 ELISA and PCFIA. Mouse MAb OkT4A is directed at an epitope within the gp120-binding domain of the CD4 receptor. Binding of OkT4A to CD4 prevents gp120-CD4 interactions (9, 14) . The capacity of OkT4A to act as a specific inhibitor in the PCFIA and ELISA demonstrates that these assays measure a specific interaction between CD4 and gpl20. Conversely, the addition of LyT2, a mouse MAb with anti-CD8a specificity (6), produced no inhibition in the ELISA and only a slight inhibition of binding in the PCFIA (Fig. 2) .
Activity of known inhibitors in gp120-CD4 binding assays. A number of polycarboxylic acid-like compounds, such as dextran sulfate (DS) and pentosan polysulfate (PPS), are known to be inhibitors of gp120-CD4 interactions (5) . As expected, they were also potent inhibitors in the gp120-CD4 binding assays (Table 1) . UK-22,233, a polymer of the chemical entity shown in Fig. 3A , was also potent in these assays. DS 5,000 and PPS were also inhibitory in the PCFIA assay and ELISA (Table 1) .
CPF(DD) and CPF(LL) were synthesized as potent anti-HIV agents whose mechanism of action was to sequester gpl20 on the surface of the HIV-1 virion (3). These derivatives of the dipeptide prolylphenylalanine were tested in the gpl2O-CD4 ELISA and were shown to be relatively inactive, with 50% inhibitory concentrations (IC50s) of greater than 400 ,ug/ml (Table 1) .
Consumption assays. The ability of the gpl20 and CD4 consumption assays to distinguish inhibitors that sequester gpl20 from those that sequester CD4 was demonstrated in experiments with two neutralizing MAbs, OkT4A and NEA-9305 (4, 9, 14) (data not shown). OkT4A, an anti-CD4 MAb, produced up to 85% inhibition when it was preincubated with sCD4, but it was not inhibitory when it was preincubated with gpl20 at comparable concentrations. NEA-9305, an anti-gpl20 MAb, inhibited sCD4-gpl2O binding in the consumption assays up to 80% when it was preincubated with gpl20, but produced no inhibition when it was preincubated with CD4 at these same concentrations.
The dipeptide inhibitor CPF(LL) has been reported to bind to gpl20 and block its interaction with CD4, leading to a block of HIV-1 infectivity (3). We have shown that it is more active when it is preincubated with gpl20 than with CD4 (Table 2) , in agreement with the data of Finberg et al. (3) .
Some anionic polysaccharides such as DS 500,000 seem to bind to CD4 (13) , while others such as PPS bind more strongly to gpl20 (15) . In our assays, PPS interacted with gp120 but not sCD4 at doses as high as 50 ,ug/ml ( Table 2) . (7, 1 LyT2 is specific for one within CD8a (6) .
Pradimicin A is a natural product with anti-HIP (12, 17, 18) . It was fermented and isolated from Actinomadura hibisca and was shown to be an gpl20-sCD4 interactions in the ELISA (IC50, 27.5 the gpl20 consumption ELISA, binding primari (IC50, 9 ,g/ml) ( Tables 1 and 2 ).
Novel gpl20-CD4 antagonists. In the screening X of compounds that have activity as gpl20-CD4 anta discovered. A synthetic agent, CP-101,816 (Fig. 3B) v inhibit the interaction of gpl20 with CD4 in the E 32.5 ,ug/ml; (Table 2) . Tanabe-Tochikura et al. (18) have shown that pradimicin A is a potent inhibitor of HIV-1 replication and syncytium formation in vitro. Pradimicin A is also a potent inhibitor in the cell-free gpl2O-sCD4 ELISA, with an IC50 of 27.5 ,ug/ml (Table 1 ). In the consumption assays it binds exclusively to gpl20 at doses of up to 125 ,ug/ml (Table 2 ). In addition, it inhibits gpl2O-CD4-mediated cell fusion in the CCSA, with an IC50 of 2.0 ,ug/ml ( Table 1) .
The gp12O-CD4 ELISA and PCFIA were used to screen for novel compounds that inhibit the interaction of gpl20 and CD4. The 2,4-diaminoquinazoline analog CP-101,816-1 was detected as an inhibitor in the ELISA (Table 1) and was the only compound tested that bound significantly to CD4 in the consumption assays (Table 2) . Fluorescence-activated cell sorter analysis with human T lymphocytes confirmed that this compound has the capacity to inhibit the binding of CD4-specific MAbs to T cells (data not shown).
Active compounds were tested in cell-based cytotoxicity assays and other assays by cocultivation of gpl20-and CD4-expressing cell lines (CCSA) (21) . In the absence of inhibitors these cells fuse and produce giant, multinucleate syncytia. In general, when toxicity did not preclude accurate testing, potency in the acellular assays was correlated with activity in syncytial assays, although pradimicin A and CP-101,816-1 were 14-and 28-fold more potent, respectively, in the cell-based assay (Table 1 ). This may have been due to the increased level of solubilization of these compounds in the CCSA over the 24 to 48 h of incubation at 37°C.
